Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action and technical parameters suggest increasing downside pressure, raising concerns for investors amid a challenging market backdrop.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price action and technical indicators reveal a nuanced picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in price momentum, reflected in a recent downgrade of its technical rating from Hold to Sell. The stock’s technical indicators reveal a transition towards bearish trends, with key metrics such as moving averages and Bollinger Bands signalling increased downside risk. This analysis delves into the technical parameters shaping the stock’s outlook and contextualises its performance against broader market benchmarks.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with the latest insights into its performance and outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a shift from the previous Hold status. However, the analysis and financial metrics discussed here represent the stock’s current position as of 11 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals and market performance.

Glaxosmithkline Pharmaceuticals Ltd recorded a robust intraday performance on 10 Feb 2026, surging 6.14% to touch a day’s high of Rs 2,632.9. The stock outperformed its sector and the broader market, reflecting heightened trading activity and notable volatility throughout the session.

Glaxosmithkline Pharmaceuticals Ltd has delivered a robust quarterly performance for the December 2025 quarter, marking a significant positive shift in its financial trend after a period of stagnation. The company posted record-high revenues and profitability metrics, signalling renewed operational strength despite some lingering concerns over liquidity and debtor management.

GlaxoSmithKline Pharmaceuticals Ltd. reported a robust third quarter for FY2026, with net profit surging 28.60% year-on-year to ₹295.62 crores and 14.81% sequentially from Q2 FY26. The pharmaceutical major, commanding a market capitalisation of ₹44,413 crores, demonstrated impressive operational efficiency with operating margins expanding to 35.66%, the highest in recent quarters. However, the stock declined 2.89% following the results announcement, trading at ₹2,590.00 on February 13, reflecting investor concerns about stretched valuations and modest long-term growth trajectory.

Glaxosmithkline Pharmaceuticals Ltd has exhibited a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a recent day gain of 1.75%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the evolving technical landscape of the stock, contextualising its performance against broader market trends and sectoral benchmarks.

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 31 January 2026, providing investors with the latest insights into its performance and valuation.

Glaxosmithkline Pharmaceuticals Ltd demonstrated robust intraday performance on 22 Jan 2026, surging to an intraday high of Rs 2,391.35, marking a 5.16% increase. The stock outperformed its sector and the broader market, reflecting strong trading momentum amid a mixed market backdrop.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a shift in the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 09 January 2026, providing investors with the latest insights into its performance and valuation.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.